Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia characterized by the accumulation of promyelocytes in the bone marrow and blood. Recent research has focused on improving ...

The introduction of all-trans retinoic acid in 1985 combined with anthracycline-based chemotherapy has revolutionized the prognosis of acute promyelocytic leukemia (APL) with current complete ...

The research, published in the July issue of the journal Cancer Cell, published by Cell Press, illuminates specific mechanisms involved in development of acute promyelocytic leukemia . The ...

Although treatment of newly diagnosed APL with anthracycline-based chemotherapy combined with ATRA has been shown to be highly effective, limiting exposure to cytotoxic chemotherapy and ...

Acute Myeloid Leukaemia (AML) with Retinoic acid receptor-gamma (RARG) fusions have similarities to Acute Promyelocytic Leukemia (APL) but are not responsive to standard APL treatments.

identifies a variant in an aggressive form of acute myelogenous leukemia (AML) known as acute promyelocytic leukemia, or APL. This variant is often missed by conventional cytogenetic techniques.